ALK and non-small cell lung carcinoma: Furthermore, ceritinib (LDK378), a more potent second-generation tyrosine kinase inhibitor with higher anaplastic lymphoma kinase (ALK) selectivity than crizotinib (19), has been investigated and shown to be active against NSCLC.